Intravenous bisphosphonate therapy for osteoporosis: where do we stand?
The use of oral bisphosphonates, particularly members of the aminobisphosphonate subclass, is well established for the treatment of osteoporosis. In a number of clinical settings, intravenous administration appears to be advantageous. However, current dosing and efficacy data are limited while definitive, long-term trials with some of these agents are ongoing. In this article, we review the available information and discuss the use of these drugs on that basis.
Bone
Henry G
HG
Michigan Bone and Mineral Clinic, 22201 Moross Road, Suite 260, Detroit, MI 48236, USA.
Schurr
Werner
W
D000368:Aged; D001682:Biological Availability; D004164:Diphosphonates / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D005544:Forecasting; D005598:Fractures, Spontaneous / Q000517:prevention & control*; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D010024:Osteoporosis / Q000175:diagnosis / Q000188:drug therapy*; D015663:Osteoporosis, Postmenopausal / Q000175:diagnosis / Q000188:drug therapy; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014481:United States
D004164:Diphosphonates